There are a lot of options for investors to choose from on the ASX 200. Two that could be in the buy zone right now are listed below.
Here’s why analysts rate them as buys:
Aristocrat Leisure Limited (ASX: ALL)
The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world’s leading gaming technology companies responsible for many of the most popular pokie machines globally. In addition to this, the company has a growing digital business with a portfolio of hugely popular mobile games such as RAID: Shadow Legends. It is also in the process of acquiring UK listed real money gaming business Playtech for $3.9 billion.
Morgans is a fan of the company and currently has an add rating and $52.00 price target on its shares.
It commented: “We reiterate our ADD rating. In our opinion, the acquisition of PTEC gives ALL the opportunity to get to scale quickly in a market segment forecast to grow at a double-digit rate over the next five years. We expect the strong sector growth to be driven by a North America market growing at a CAGR of close to 50% as more US states liberalise and allow online iGaming and online sports betting.”
CSL Limited (ASX: CSL)
Another ASX 200 share that could be in the buy zone is CSL. It is one of the world’s leading biotechnology companies, comprising the CSL Behring and Seqirus businesses. Both are leaders in their respective fields – plasma therapies and vaccines.
Citi is bullish on the company, particularly following its Vifor Pharma acquisition announcement, and appears to see the weakness in the CSL share price as a buying opportunity for investors. It has a buy rating and $340.00 price target on its shares.
Citi said: “CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow.”